Synonym
Tofenacin hydrochloride; Tofenacin HCl; BS7331; BS-7331; BS 7331
IUPAC/Chemical Name
Ethanamine, N-methyl-2-((2-methylphenyl)phenylmethoxy)-, hydrochloride
InChi Key
YAXWIYFUVISXRS-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)17(19-13-12-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H
SMILES Code
CC1=CC=CC=C1C(C2=CC=CC=C2)OCCNC.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
291.82
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine. Pharmacopsychiatry. 1989 Nov;22(6):246-9. doi: 10.1055/s-2007-1014608. PMID: 2616635.
2: Contin M, Riva R, Albani F, Baruzzi A. Simple and rapid GLC method for the determination of orphenadrine in human plasma. Biomed Chromatogr. 1987;2(5):193-4. doi: 10.1002/bmc.1130020504. PMID: 3507235.
3: Bast A, Savenije-Chapel EM, van Kemenade FA, Scheefhals LW, Noordhoek J. Effect of multiple administration of orphenadrine or mono-N- desmethylorphenadrine on cytochrome P-450 catalyzed reactions in the rat. Arch Toxicol. 1983 Oct;54(2):131-7. doi: 10.1007/BF01261381. PMID: 6651526.
4: Bast A, van Kemenade FA, Savenije-Chapel EM, Noordhoek J. Product inhibition in orphenadrine metabolism as a result of a stable cytochrome P-450-metabolic intermediate complex formed during the disposition of mono-N- desmethylorphenadrine (tofenacine) in the rat. Res Commun Chem Pathol Pharmacol. 1983 Jun;40(3):391-403. PMID: 6622816.
5: Crome P. Antidepressant overdosage. Drugs. 1982 Jun;23(6):431-61. doi: 10.2165/00003495-198223060-00002. PMID: 6213400.
6: Capstick N, Pudney H. A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy. J Int Med Res. 1976;4(6):435-40. doi: 10.1177/030006057600400610. PMID: 800383.
7: Hespe W, Kafoe WF. Aspects of the biliary excretion of orphenadrine and its N-demethylated derivative, tofenacin, in the rat. Eur J Pharmacol. 1970;13(1):113-22. doi: 10.1016/0014-2999(70)90191-3. PMID: 5496919.
